Fosun Pharma: Plans to invest 414 million yuan to participate in the Series B financing and equity transfer of innovative liver disease drug company Star-X Therapeutics
Fosun Pharma is investing 414 million yuan in a Series B funding round for Xingyao Kunze, a company focused on innovative liver disease drugs. This investment, which includes acquiring shares from existing shareholders, will give Fosun Pharma a 20.87% stake in Xingyao Kunze. The move aims to expand Fosun Pharma's pipeline in liver disease treatments. AI
IMPACT Minimal direct impact on AI operators; focuses on pharmaceutical R&D.